Pedro Maria, DO
Payments from drug & device makers
Across 985 payments — averaging $245.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$211K
- Axogen$9K
- Davol Inc.$6K
- Kerecis Limited$3K
- Neotract Inc.$2K
- Boston Scientific$2K
- plus $9K from 30 others
What the payments were for
- Consulting fees$129,10553%
- Travel & lodging$28,49112%
- Food & beverage$34,92214%
- Education$49,41420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 650 | $210,861 |
| Axogen | 41 | $9,081 |
| Davol Inc. | 31 | $5,903 |
| Kerecis Limited | 6 | $3,241 |
| Neotract Inc. | 18 | $2,254 |
| Boston Scientific | 46 | $1,819 |
| Teleflex LLC | 15 | $1,150 |
| Endo Pharmaceuticals Inc. | 43 | $959 |
| Astellas Pharma US Inc | 31 | $800 |
| Johnson & Johnson(2 entities) | 15 | $695 |
| BD | 4 | $684 |
| Palette Life Sciences, Inc. | 4 | $551 |
| Sumitomo Pharma America, Inc. | 21 | $484 |
| Calyxo, Inc. | 4 | $401 |
| Endo USA, Inc. | 10 | $301 |
| Procept Biorobotics Corporation | 2 | $298 |
| Progenics Pharmaceuticals, Inc. | 4 | $282 |
| Rigicon,inc. | 4 | $265 |
| Axonics, Inc. | 5 | $249 |
| Novartis | 3 | $233 |
| Pfizer | 7 | $232 |
| Medtronic | 3 | $204 |
| Urogen Pharma, Inc. | 1 | $175 |
| KARL Storz Lithotripsy-america | 1 | $150 |
| Contura, Inc. | 3 | $140 |
| Angiodynamics, Inc. | 1 | $132 |
| Ambu Inc. | 2 | $89 |
| Antares Pharma, Inc. | 1 | $50 |
| Laborie Medical Technologies Corp. | 1 | $45 |
| Dendreon Pharmaceuticals LLC | 1 | $45 |
| AstraZeneca | 1 | $35 |
| Myriad Genetic Laboratories, Inc. | 1 | $35 |
| Acerus Pharmaceuticals Corporation | 2 | $34 |
| Avanos Medical | 1 | $24 |
| Intuitive Surgical | 1 | $17 |
| Tolmar, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TITAN$196,742
- AXOGUARD$10,300
- Kerecis Omega3 SurgiClose$9,097
- AXOGUARD HA+ NERVE PROTECTOR$6,362
- AxoGuard Nerve Cap$6,362
- ARISTA AH FLEXITIP$4,265
- Kerecis Omega3 Marigen$3,791
- Kerecis Omega3 GraftGuide$3,222
- UroLift$2,290
- AVANCE NERVE GRAFT$2,060
- ALTIS$1,500
- AxoGuard Nerve Connector$1,212
- AxoGuard Nerve Protector$1,212
- PROGEL$655
- Phasix Mesh$451
- ARISTA$419
- VIRTUE$351
- Barrigel$294
- Echelon Flex$271
- CVAC Aspiration System$250
How this compares
$241,931 in reported general payments places this provider in the 95th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 31 | $16,735 |
| Tamsulosin Hcl | 234 | $1,703 |
| Oxybutynin Chloride ErOxybutynin Chloride | 79 | $976 |
| Finasteride | 149 | $643 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 29 | $388 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 17 | $323 |
| Gabapentin | 22 | $217 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 24 | $202 |
| Ciprofloxacin Hcl | 33 | $162 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 45 | $104 |
| Chlorthalidone | 11 | $96 |
| Naproxen | 13 | $73 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 11 | $70 |
| Paroxetine Hcl | 11 | $65 |
| Oxycodone Hcl | 16 | $29 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $484 | $16,73531 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 952 urology providers in New York.
Other urology in Bronx
- Bhupendra ToliaBronx$257K
- Glen McWilliamsBronx$235K
- Christopher PieczonkaSyracuse$31.2M
- Guarionex DecastroNew York$5.7M
- Mitchell EfrosGarden City$4.2M
- James McKiernanNew York$4.1M
- William HuangNew York$3.9M
- Jed KaminetskyMiddle Village$3.5M
- Evan GoldfischerPoughkeepsie$3.1M
- Gennady BratslavskySyracuse$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.